INTS vs NDAQ · $7.7M cap vs P/E 41, rev $8.26B
Intensity Therapeutics, Inc. Common stock (INTS) versus Nasdaq Inc (NDAQ) — a side-by-side from cached financials, not a winner call.
Intensity Therapeutics, Inc. Common stock (INTS) is a biotechnology company listed on US.
Nasdaq Inc (NDAQ) is a financial data & stock exchanges company listed on US.
INTS does not have a complete income-statement cache yet.
Latest reported NDAQ revenue for 2025-12-31 was $8.26B. Net income was $1.79B. Revenue was up 11.6% from 2024-12-31 to 2025-12-31. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
INTS currently screens at market cap $7.7M. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
Not investment advice. Open the INTS and NDAQ stock pages for the full models.
Not investment advice.